Cargando…

Novel Tools for Diagnosis and Monitoring of AML

In recent years, major advances in the understanding of acute myeloid leukemia (AML) pathogenesis, together with technological progress, have led us into a new era in the diagnosis and follow-up of patients with AML. A combination of immunophenotyping, cytogenetic and molecular studies are required...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guijarro, Francesca, Garrote, Marta, Villamor, Neus, Colomer, Dolors, Esteve, Jordi, López-Guerra, Mónica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297692/ https://www.ncbi.nlm.nih.gov/pubmed/37366878 http://dx.doi.org/10.3390/curroncol30060395

Ejemplares similares

P532: KINETICS AND PROGNOSTIC VALUE OF MEASURABLE RESIDUAL DISEASE (MRD) IN PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS.
por: Jimenez-Vicente, Carlos, et al.
Publicado: (2023)

Chronic lymphocytic leukemia and prolymphocytic leukemia. Two coins or two sides of the same coin?
por: Magnano, Laura, et al.
Publicado: (2020)

Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing
por: Garrote, Marta, et al.
Publicado: (2023)

Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia
por: Giménez, Neus, et al.
Publicado: (2019)

P1054: CLINICAL CHARACTERISTICS AND OUTCOMES IN 175 PATIENTS WITH MYELOFIBROSIS ACCORDING TO GENOMIC CLASSIFICATION USING NEXT-GENERATION SEQUENCING
por: Garrote Ordeig, Marta, et al.
Publicado: (2023)

The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia
por: Xargay-Torrent, Sílvia, et al.
Publicado: (2015)

Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets
por: López-Oreja, Irene, et al.
Publicado: (2021)

Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome
por: Guijarro, Francesca, et al.
Publicado: (2023)

Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes
por: Castaño-Díez, Sandra, et al.
Publicado: (2022)

Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells
por: López-Guerra, Mónica, et al.
Publicado: (2019)

Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution
por: Rivero, Andrea, et al.
Publicado: (2021)

CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia
por: Montraveta, Arnau, et al.
Publicado: (2015)

Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient
por: Nielsen, Torsten H., et al.
Publicado: (2013)

Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies
por: Delgado, Julio, et al.
Publicado: (2020)

Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia
por: Giménez, Neus, et al.
Publicado: (2019)

Clinico‐biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation
por: Bastidas‐Mora, Gabriela, et al.
Publicado: (2021)

Straight to the Point—The Novel Strategies to Cure Pediatric AML
por: Lejman, Monika, et al.
Publicado: (2022)

MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?
por: Pessach, Ilias, et al.
Publicado: (2022)

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
por: Assouline, Sarit, et al.
Publicado: (2012)

CDK6 Inhibition: A Novel Approach in AML Management
por: Uras, Iris Z., et al.
Publicado: (2020)

Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia
por: Gimenez, Neus, et al.
Publicado: (2020)

Exploiting Clonal Evolution to Improve the Diagnosis and Treatment Efficacy Prediction in Pediatric AML
por: Bertuccio, Salvatore Nicola, et al.
Publicado: (2021)

The role of the proteasome in AML
por: Csizmar, C M, et al.
Publicado: (2016)

FLIM as a Promising Tool for Cancer Diagnosis and Treatment Monitoring
por: Ouyang, Yuzhen, et al.
Publicado: (2021)

Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia
por: Mozas, Pablo, et al.
Publicado: (2018)

Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review
por: Teixeira, Alexandra, et al.
Publicado: (2023)

Emerging agents and regimens for AML
por: Liu, Hongtao
Publicado: (2021)

Detection of chromothripsis‐like patterns with a custom array platform for chronic lymphocytic leukemia
por: Salaverria, Itziar, et al.
Publicado: (2015)

Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer
por: de Freitas, Ana Julia Aguiar, et al.
Publicado: (2022)

Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches
por: Winer, Eric S., et al.
Publicado: (2019)

Rational biomarker development for the early and minimally invasive monitoring of AML
por: Abdelhamed, Sherif, et al.
Publicado: (2021)

Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
por: Raut, Lalit S.
Publicado: (2015)

Bioinformatic Tools for NGS-Based Metagenomics to Improve the Clinical Diagnosis of Emerging, Re-Emerging and New Viruses
por: Ibañez-Lligoña, Marta, et al.
Publicado: (2023)

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
por: Bataller, Alex, et al.
Publicado: (2022)

Novel Biomarkers for Diagnosis and Monitoring of Immune Thrombocytopenia
por: Allegra, Alessandro, et al.
Publicado: (2023)

Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC)
por: Arber, Daniel A, et al.
Publicado: (2020)

Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma
por: Rosich, Laia, et al.
Publicado: (2014)

SF3B1 mutation–mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia
por: López-Oreja, Irene, et al.
Publicado: (2023)

The Challenge of AML in Older Patients
por: Burnett, Alan K
Publicado: (2013)

Treatments for children and adolescents with AML
por: Kim, Hyery
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6oqkh46vp7slfci8skbuotos4h